RPRX
Income statement / Annual
Last year (2024), Royalty Pharma plc's total revenue was $2.26 B,
a decrease of 3.86% from the previous year.
In 2024, Royalty Pharma plc's net income was $858.98 M.
See Royalty Pharma plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.26 B |
$2.35 B |
$2.24 B |
$2.29 B |
$2.12 B |
$1.81 B |
$1.79 B |
$1.60 B |
$1.88 B |
$1.65 B |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$230.84 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$2.26 B
|
$2.35 B
|
$2.24 B
|
$2.29 B
|
$1.89 B
|
$1.81 B
|
$0.00
|
$0.00
|
$1.88 B
|
$1.65 B
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
0.89
|
1
|
0
|
0
|
1
|
1
|
| Research and Development Expenses |
$2.00 M
|
$52.00 M
|
$177.11 M
|
$200.08 M
|
$26.29 M
|
$83.04 M
|
$392.61 M
|
$117.87 M
|
$91.02 M
|
$98.38 M
|
| General & Administrative Expenses |
$236.67 M
|
$249.75 M
|
$227.30 M
|
$182.83 M
|
$181.72 M
|
$103.44 M
|
$61.91 M
|
$106.44 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$236.67 M
|
$249.75 M
|
$227.30 M
|
$182.83 M
|
$181.72 M
|
$103.44 M
|
$61.91 M
|
$106.44 M
|
$69.51 M
|
$121.42 M
|
| Other Expenses |
$732.46 M
|
$560.66 M
|
$1.53 B
|
$475.84 M
|
$88.11 M
|
-$995.40 M
|
-$24.07 M
|
$433.93 M
|
$925.80 M
|
$570.18 M
|
| Operating Expenses |
$971.13 M
|
$862.40 M
|
$1.93 B
|
$858.75 M
|
$296.12 M
|
-$808.92 M
|
$430.45 M
|
$658.24 M
|
$1.09 B
|
$789.98 M
|
| Cost And Expenses |
$971.13 M
|
$862.40 M
|
$1.93 B
|
$858.75 M
|
$526.95 M
|
-$808.92 M
|
$430.45 M
|
$658.24 M
|
$1.15 B
|
$858.14 M
|
| Interest Income |
$47.34 M
|
$72.29 M
|
$78.34 M
|
$53.54 M
|
$28.38 M
|
$22.33 M
|
$24.44 M
|
$6.76 M
|
$0.00
|
$0.00
|
| Interest Expense |
$225.51 M
|
$187.19 M
|
$187.96 M
|
$166.14 M
|
$157.06 M
|
$268.57 M
|
$279.96 M
|
$247.34 M
|
$238.92 M
|
$224.42 M
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$5.67 M
|
$23.00 M
|
$23.06 M
|
$23.92 M
|
$33.27 M
|
$33.27 M
|
$68.20 M
|
$68.16 M
|
| EBITDA |
$1.56 B |
$1.89 B |
$423.70 M |
$1.43 B |
$1.68 B |
$2.75 B |
$1.83 B |
$1.62 B |
$1.07 B |
$862.44 M |
| EBITDA Ratio |
0.69
|
0.8
|
0.19
|
0.62
|
0.79
|
1.52
|
1.02
|
1.02
|
0.57
|
0.52
|
| Operating Income Ratio |
0.57
|
0.63
|
0.14
|
0.62
|
0.75
|
1.45
|
0.76
|
0.59
|
0.39
|
0.48
|
| Total Other Income/Expenses Net |
$38.37 M
|
$207.94 M
|
-$77.00 M
|
-$189.51 M
|
$106.56 M
|
-$161.76 M
|
$153.41 M
|
$403.49 M
|
$39.02 M
|
-$35.57 M
|
| Income Before Tax |
$1.33 B
|
$1.70 B
|
$230.06 M
|
$1.24 B
|
$1.70 B
|
$2.46 B
|
$1.52 B
|
$1.34 B
|
$761.90 M
|
$758.71 M
|
| Income Before Tax Ratio |
0.59
|
0.72
|
0.1
|
0.54
|
0.8
|
1.36
|
0.85
|
0.84
|
0.41
|
0.46
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
$858.98 M
|
$1.13 B
|
$42.83 M
|
$619.73 M
|
$975.04 M
|
$2.35 B
|
$1.38 B
|
$1.21 B
|
$565.91 M
|
$581.43 M
|
| Net Income Ratio |
0.38
|
0.48
|
0.02
|
0.27
|
0.46
|
1.29
|
0.77
|
0.76
|
0.3
|
0.35
|
| EPS |
1.92 |
2.54 |
0.1 |
1.49 |
2.51 |
6.63 |
3.89 |
3.42 |
0.93 |
0.96 |
| EPS Diluted |
1.91 |
2.53 |
0.1 |
1.49 |
2.51 |
6.63 |
3.89 |
3.42 |
0.93 |
0.96 |
| Weighted Average Shares Out |
$445.99 M
|
$447.60 M
|
$437.96 M
|
$414.79 M
|
$388.14 M
|
$354.18 M
|
$354.18 M
|
$354.18 M
|
$607.04 M
|
$607.04 M
|
| Weighted Average Shares Out Diluted |
$594.00 M
|
$602.90 M
|
$437.97 M
|
$414.80 M
|
$388.14 M
|
$354.18 M
|
$354.18 M
|
$354.18 M
|
$607.04 M
|
$607.04 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
